Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Current Leases (2021 - 2025)

Prime Medicine (PRME) has disclosed Current Leases for 5 consecutive years, with $8.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 125.15% year-over-year to $8.1 million, compared with a TTM value of $8.1 million through Dec 2025, up 125.15%, and an annual FY2025 reading of $8.1 million, up 125.15% over the prior year.
  • Current Leases was $8.1 million for Q4 2025 at Prime Medicine, up from $7.7 million in the prior quarter.
  • Across five years, Current Leases topped out at $13.5 million in Q2 2023 and bottomed at $3.6 million in Q4 2024.
  • Average Current Leases over 5 years is $8.4 million, with a median of $7.7 million recorded in 2025.
  • The sharpest move saw Current Leases plummeted 61.39% in 2024, then surged 125.15% in 2025.
  • Year by year, Current Leases stood at $7.3 million in 2021, then surged by 59.41% to $11.7 million in 2022, then fell by 20.68% to $9.3 million in 2023, then crashed by 61.04% to $3.6 million in 2024, then soared by 125.15% to $8.1 million in 2025.
  • Business Quant data shows Current Leases for PRME at $8.1 million in Q4 2025, $7.7 million in Q3 2025, and $7.3 million in Q2 2025.